2023
Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023)
Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023). Small Methods 2023, 7 DOI: 10.1002/smtd.202370057.Peer-Reviewed Original Research
2021
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales MA, Seropian S, Shaw BE, Tuschl EE, Zeidan AM, Riches ML, Shah GL. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. The Lancet Haematology 2021, 8: e185-e193. PMID: 33482113, PMCID: PMC7816949, DOI: 10.1016/s2352-3026(20)30429-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAllogeneic HSCT recipientsAutologous HSCT recipientsHaematopoietic stem cell transplantation recipientsStem cell transplantation recipientsCOVID-19 diagnosisHSCT recipientsNational Cancer InstituteHigh riskAllogeneic HSCTOverall survivalTransplantation recipientsCOVID-19Cancer InstituteCox proportional hazards modelAggressive treatment measuresSurvival 30 daysObservational cohort studyMarrow Transplant ResearchPoor overall survivalAge 50 yearsOverall survival probabilityPlasma cell disordersMonths of transplantationProportional hazards modelNational Institute